Chronic Lymphocytic Leukemia | Clinical

Real-World Study Shows Limited Implementation of Recommended Biomarker Testing in CLL

May 04, 2021

In an interview with Targeted Oncology, Mato, a hematologic oncologists and the director of the CLL Program at Memorial Sloan Kettering Cancer Center, discussed biomarker testing in CLL, and the future of BTK inhibitors in the CLL paradigm. 

Zanubrutinib Shown Noninferior to Ibrutinib for Patients With R/R CLL/SLL

April 29, 2021

The use of zanubrutinib was found to be noninferior to treatment with ibrutinib for adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, meeting the primary end point of the phase 3 ALPINE trial.

Ibrutinib Extends PFS in Patients with TP53-Mutated Chronic Lymphocytic Leukemia

March 30, 2021

In an interview with Targeted Oncology, John N. Allan, MD, a hematology oncologist at Weill Cornell Medicine, discussed how ibrutinib extends PFS in patients with CLL. He also discussed combination therapy in the future of CLL treatment.

Clinical Benefit Demonstrated With Ublituximab Plus Ibrutinib in R/R CLL

March 15, 2021

Patients with relapsed or refractory high-risk chronic lymphocytic leukemia achieved a statistically higher rate of overall response when the glycoengineered, type I anti-CD20 monoclonal antibody ublituximab was added to the Bruton’s tyrosine kinase inhibitor ibrutinib, according to results from the phase 3 GENUINE study.